Product Description
Mechanisms of Action: OXTR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Obesity|Surgical Wound Infection
Phase 2: Premature Ejaculation|Obstetric Labor, Premature|Adenomyosis
Phase 1: Healthy Volunteers|Premature Ejaculation|Pain Unspecified|Obstetric Labor, Premature
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02213029 |
Study IVF116828 | P1 |
Terminated |
Healthy Volunteers|Pain Unspecified |
2016-02-07 |
2019-03-20 |
Treatments |
|
NCT02703181 |
NCT02703181 | P1 |
Completed |
Healthy Volunteers |
2015-09-10 |
2019-03-20 |
Treatments |
|
NCT02257359 |
NCT02257359 | P1 |
Completed |
Healthy Volunteers |
2015-01-29 |
2019-03-20 |
Treatments |
|
NCT01669083 |
NCT01669083 | P1 |
Completed |
Healthy Volunteers |
2013-03-09 |
2019-03-19 |
Treatments |
|
NCT00549211 |
OTB109039 | P1 |
Completed |
Premature Ejaculation|Obstetric Labor, Premature |
None |
2019-03-22 |
Treatments |
|
NCT02794467 |
NCT02794467 | P2 |
Withdrawn |
Adenomyosis |
2016-10-01 |
2019-03-20 |
||
NCT01021553 |
NCT01021553 | P2 |
Completed |
Obstetric Labor, Premature|Premature Ejaculation |
2011-05-05 |
2019-03-19 |
Treatments |
|
2009-011855-40 |
2009-011855-40 | P2 |
Completed |
Premature Ejaculation |
2010-08-26 |
2022-03-13 |
Treatments |
|
ACTRN12620000004965p |
MCC-21-18040 | P4 |
Not yet recruiting |
Obesity|Surgical Wound Infection |
2020-08-24 |